Gastroparesis Clinical Trial
Official title:
Idiopathic Gastroparesis Registry to Define Severity, Treatment Response, and Prognosis Using a Predominant-Symptom Classification
The diagnosis of "gastroparesis" suggests that delayed gastric emptying is the underlying cause of symptoms, but this description fails to explain the variable presentation. There are fundamental differences in causes, symptoms, and prognosis among patients with idiopathic gastroparesis. Understanding these differences is necessary in order to provide effective treatment in these patients. We believe our classification for gastroparesis is a useful tool in the management of patients with idiopathic gastroparesis to predict clinical severity, treatment response, and future prognosis.
"Idiopathic gastroparesis" is a poor term to describe this very heterogeneous syndrome.
Pathophysiology may not be "idiopathic," but merely unidentifiable with conventional methods
suggested for gastroparesis. The diagnosis of "gastroparesis" suggests that delayed gastric
emptying is the underlying cause of symptoms, but this description fails to explain the
variable presentation. There are fundamental differences in pathophysiology, clinical
presentation, severity, and future prognosis among patients with idiopathic gastroparesis.
Understanding these differences is necessary in order to provide cost-effective treatment in
these patients.
We believe our clinical classification for gastroparesis is a clinical useful tool in the
management of patients with idiopathic gastroparesis to predict clinical severity, treatment
response, and future prognosis. Patients with vomiting-predominant gastroparesis will be
more likely to have an underlying cause, such as viral infection or impaired glucose
tolerance with vagal neuropathy. Their symptoms will likely be persistent. Patients with
dyspepsia-predominant gastroparesis mimic those with functional dyspepsia and are unlikely
to have complications such as weight loss, and dehydration. The necessity of enteric feeding
in these patients is also unlikely. Prokinetics may help since delayed gastric emptying may
contribute to epigastric pain or postprandial distress. Finding and treating small
intestinal bacterial overgrowth as well as suggesting lifestyle and dietary modifications
may be helpful. Patients with regurgitation-predominant gastroparesis may benefit most by
improving their delayed gastric emptying. Their gastroparesis may cause reflux-like
symptoms, especially at night.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03941288 -
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
|
Phase 2 | |
Terminated |
NCT03285308 -
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
|
Phase 3 | |
Completed |
NCT00733551 -
Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.
|
Phase 1 | |
Completed |
NCT01650714 -
Endoscopic Full Thickness Biopsy, Gastric Wall.
|
N/A | |
Completed |
NCT01452815 -
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
|
Phase 2 | |
Completed |
NCT01039974 -
GSK962040 Drug-drug Interaction Study With Ketoconazole
|
Phase 1 | |
Terminated |
NCT04844190 -
Use of EndoFLIP and Manometry Prior to G-POEM
|
N/A | |
Enrolling by invitation |
NCT06215547 -
Medtronic Enterra II Neurostimulator
|
N/A | |
Completed |
NCT04026997 -
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
|
Phase 2 | |
Completed |
NCT00562848 -
A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040
|
Phase 1 | |
Enrolling by invitation |
NCT04207996 -
Vagus Nerve Response in Gastroparesis Patients
|
||
Completed |
NCT04607304 -
ABCA2 GIRMS Analytical Validation Clinical Performance Study
|
N/A | |
Recruiting |
NCT06068114 -
Gastric Pathophysiology in Diabetes
|
||
Completed |
NCT03259841 -
Ultrasound Assessment of Gastric Contents in Fasted Patient Undergoing Cholecystectomy
|
||
Active, not recruiting |
NCT04300127 -
Pioglitazone for Idiopathic Gastroparesis
|
Early Phase 1 | |
Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
Terminated |
NCT04635306 -
13C-Spirulina Nitrogen Content GEBT Study
|
N/A | |
Withdrawn |
NCT02420925 -
Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis
|
N/A | |
Recruiting |
NCT00777439 -
Domperidone for Refractory Gastrointestinal Disorders
|
N/A | |
Terminated |
NCT00760461 -
Domperidone in Refractory Gastroparesis
|
Phase 2 |